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Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical
models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled
to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2)
and granulocyte-macrophage colony stimulating factor (GM-CSF). Promising antitumor
effects in metastatic colorectal cancer (mCRC) patients were obtained in previous phase
II and III trials. Here we report the results of 15 years of follow-up.
Methods: This is amulti-institutional retrospective analysis including 179mCRC patients
receiving GOLFIG regimen between June 2002 and June 2018. Sixty-two of them
received the treatment as frontline (enrolled in the GOLFIG-2 phase III trial) and 117 as
second/third line (49 enrolled in the GOLFIG-1 phase II trial and 68 as compassionate
use). One hundred twelve patients showed a primary left side and 67 a primary right side;
K/N-ras mutational status was available in 74 cases, and an activating mutation was
detected in 33. Kaplan–Meier and Cox regression analyses were carried out to relate
PFS and OS with different parameters.
Results: Overall, we recorded a mean PFS and OS of 15.28 (95% CI: 10.36–20.20)
and 24.6 (95% CI: 19.07–30.14) months, respectively, with 14 patients surviving free
of progression for 10 years. This regimen, in our updated survey of the GOLFIG-2 trial,
confirmed superiority over FOLFOX in terms of PFS (hazard ratio (HR)= 0.58, p= 0.006)
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with a trend to a longer OS (HR = 0.69, P = 0.06) in the first line. Our analysis also
confirmed significant antitumor activity in pre-treated patients, reporting a mean PFS and
OS of 12.55 (95% CI: 7.19–17.9) and 20.28 (95% CI: 14.4–26.13) months, respectively.
Immune-related adverse events (irAEs) were recorded in 24% of the cases and were
related to a longer survival (HR = 0.36; P = 0.0001). Finally, patients’ outcome was not
correlated to sex, sidedness, and MT-K/N-ras.
Conclusions: The GOLFIG regimen is a reliable underestimated therapeutic option in
pre-treated mCRC patients and offers a strong rationale to design further trials.
Keywords: colorectal cancer, metastatic, chemotherapy, immunotherapy, GOLFIG, phase III clinical trial, real-
world medicine
INTRODUCTION
Colorectal carcinoma (CRC) is one of the leading causes of
cancer-related deaths worldwide (1). At the present, first- and
second-line treatment of metastatic CRC (mCRC) has been
well-defined and is based on the use of a fluoropyrimidine
backbone [fluorouracil (5-FU) ± capecitabine or levofolinate
(LF)] coupled to oxaliplatin (FOLFOX/CapeOX), irinotecan
(FOLFIRI/CapeIRI), or even both (FOLFOXIRI). Monoclonal
antibody (mAB) therapy may also be associated, for example,
with bevacizumab, against VEGF (vascular-endothelial growth
factor) (2, 3), or with panitumumab and cetuximab, against
EGFR (epidermal growth factor receptor) (3, 4) (only applicable
if patients are not expressing mutations that activate K/N-ras)
(5). An alternative use of these regimens is recommended in the
second line with no real difference in terms of outcome, with
the only exception of the regimen of FOLFIRI and aflibercept,
an anti-angiogenetic recombinant protein able to trap VEGF
A/B and the placental growth factor (PlGF), which showed an
advantage over chemotherapy alone in terms of response rate
(RR) (19.8 vs. 11.1%; P = 0.0001), PFS [6.90 vs. 4.67 months;
hazard ratio (HR) = 0.758; IC95% 0.661–0.869; P < 0.0001],
and OS (13.50 vs. 12.06 months; HR = 0.817; IC34% 0.713–
0.937; P = 0.032). The latter regimen, however, is reserved for
fit patients since it is associated with potentially severe adverse
events including bleeding, hypertension, infections, and gastro-
enteric and hematological toxicity in almost 30% of the patients
who refuse to continue the treatment (6, 7). Almost half of mCRC
patients over second-line disease progression are still fit to receive
further treatments with regorafenib or trifluridine/tipiracil. The
first one is a multi-kinase inhibitor with potent anti-angiogenetic
and cytostatic effects, while the second is a DNA-damaging
cytotoxic pro-drug. Both of them, investigated in two multi-
institutional phase III trials (CORRECT and RECOURSE trials)
in pre-treated mCRC patients, reported similar advantage over
best supportive care (BSC) in terms of PFS (2 vs. 1.7; p < 0.001)
and OS (6–7 vs. 5 months; P < 0.01) but with severe and drug-
specific adverse events and costs (8–10). Overall, the survival
of mCRC patients remains in the range of 26–28 months, with
no real improvement achieved in the last 10 years. On these
bases, research on new and more active treatment strategies is
strongly needed.
In the last few years, the interest in the use of immunological
anticancer strategies is greatly increased due to the clinical
development of PD-1/PDL-1 immune-checkpoint blockade with
mABs (11, 12). Although very active in the treatment of
aggressive and heterogeneous malignancies such as NSCLC,
malignant melanoma, and head and neck and esophageal cancer,
these strategies resulted as inactive in mCRC patients not bearing
specific deficit in the mismatch repair complex and microsatellite
instability, usually expressed in <5% of cases (13–15).
Many different immunological strategies, including immune-
modulating agents, mAbs, cytokines, and cancer vaccines, in
mCRC patients have been evaluated in the last 25 years,
with contrasting results in terms of clinical efficacy. Even
though they failed to demonstrate a clear antitumor effect,
these studies produced a large amount of data concerning the
ability of different immune-modulating agents to trigger an
efficient tumor-specific adaptive immune response, to activate
mechanisms of immune resistance and to produce immune-
related adverse events (irAEs) (16–25).
On the track of those studies, we demonstrated the possibility
of eliciting highly efficient colon cancer–specific cytotoxic T-cell
lines (CTLs) by in vitro stimulating human peripheral blood
mononuclear cells (PBMCs) with colon cancer cells pre-exposed
to immunomodulating drugs including gemcitabine, oxaliplatin,
LF, and fluorouracil (5-FU) alone or in combination (GOLF)
and other chemo-immunological blends, such as granulocyte-
macrophage colony stimulating factor (GM-CSF) and then low-
dose human recombinant interleukin-2 (IL-2) (26, 27). GM-
CSF was used to activate the antigen-presenting ability of the
dendritic cells (DCs) expressed in human PBMCs (0.5–2% of
the whole population), while IL-2 was required to promote the
proliferation of cross-primed CTL clones (26, 27). In this context,
the GOLF multidrug combination showed the unique ability
(not shared with FOLFOX or FOLFIRI) to induce a massive
release of antigenic material from tumor cells also activating a
strong immune-danger signal able to empower the subsequent
DC-mediated cross-priming, leading to the generation of CTL
precursors with enhanced antitumor activity in vitro (26–28).
These results offered the rationale to design an innovative
treatment chemo-immunotherapy regimen aimed to mimic
the abovementioned protocol for the in vitro sensitization of
human colon cancer–specific CTLs. We combined a biweekly
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chemotherapy with gemcitabine + FOLFOX-4 (GOLF regimen)
(administered on days 1–2q15) integrated by subcutaneous (sc.)
administration of GM-CSF (sargramostim/molgramostim) to
activate peripheral DCs (days 3–7), followed by bi-daily sc.
administration of recombinant IL-2 (aldesleukin) at a very low
dose (days 8–14). (29–31). The combination of GOLF poly-
chemotherapy with GM-CSF and IL-2, designated as GOLFIG,
was evaluated by two subsequent multicenter phase II and
phase III clinical trials in mCRC patients. The GOLFIG-1 trial,
started in 2002, enrolled 46 mCRC consecutive patients who
received prior chemotherapy with fluoropyrimidine alone (12
cases), FOLFOX-4 chemotherapy alone (24), or both FOLFOX
and FOLFIRI (10 cases). It resulted as moderately safe and
showed significant immunological and antitumor activity. The
study reported a response rate (RR) and a disease control rate
(DCR) of 56.5 and 91.3%, respectively, and a mean PFS of 12.3
months (30, 31).
In these patients, to confirm its biological rationale,
the study was accompanied by ancillary immune
monitoring, which recorded a progressive treatment-
related increase in CTL precursors specific for tumor-
associated antigens such as carcino-embryonic antigen
(CEA) and thymidylate synthase (TS); an increase of
central memory-cytotoxic T-lymphocytes (CD8+CD45RA-
CCR7+) (Tcm), activated CTLs (CD8+CD62L+), and
highly cytotoxic NK (CD3-CD56+CD16+) cells; and a
parallel decline in immunosuppressive regulatory T-cells
(CD4+CD25hi+FoxP3+) (Tregs). These events were recorded
both in patients’ PBMCs and in the tumor tissue on a sample of
patients who underwent a post-treatment biopsy or palliative
surgery (30, 31).
In this first trial, we reported for the first time the evidence of
self-limiting irAEs in 19% of cases, whose appearance was highly
correlated to a favorable outcome (31–33). Altogether, those
results granted the rationale to design a subsequent multicenter
phase III trial where mCRC patients were randomized to receive
up front the GOLFIG regimen or FOLFOX-4 regimen, which,
at the time of the protocol design (2004), was considered as
the best frontline treatment for the advanced disease. The trial
enrolled 124 patients (62 per arm) before being prematurely
terminated due to the sudden withdrawal of salgramostim from
the European market and due to delayed recruitment related
to the rise of many competing phase III trials investigating
FOLFOX/FOLFIRI chemotherapy in addition to mAbs, like
bevacizumab, cetuximab, and then panitumumab. The results of
the first interim analysis of the GOLFIG-2 trial were obtained
on the first 98 censored patients (49 per arm), with a median
follow-up of 5 years. Our data indicated a clear advantage of
GOLFIG chemo-immunotherapy over the FOLFOX regimen in
terms of PFS (18.26 vs. 7.82 months, HR = 0.52, P < 0.002),
RR, and DCR, fulfilling the primary objective of the study. In
the experimental arm of the trial, we recorded irAEs in 12%
of the cases, which was strongly correlated with a very positive
outcome in terms of PFS (HR: 0.48; P = 0.031) and survival
(HR: 0.42; P = 0.028). The immune monitoring of the patients
enrolled in this second trial confirmed the same immunological
findings reported in the GOLFIG-1 only in the experimental
arm, while minimal effects were recorded in patients receiving
FOLFOX chemotherapy alone (34). These studies did not have
further experimental developments, due to the establishment of
very effective multidrug combinations with mAbs to EGFR and
VEGF, which led to the definition of solid guidelines for the first
and second treatment lines of mCRC patients. In light of the
positive premises, the GOLFIG chemo-immunological treatment
could still be used as compassionate use in a cohort of 68 mCRC
patients who had progressed through the standard sequence of
treatment and still presented an acceptable performance status
and wish for treatment.
On these bases, we decided to carry out a retrospective analysis
including all the mCRC patients who have received the GOLFIG
chemo-immunotherapy between June 2002 and December 2018.
PATIENTS AND METHODS
Study Design and Participants
This is a multi-institutional retrospective analysis assessed on a
cohort of 179 patients with mCRC who had received GOLFIG
chemo-immunotherapy between June 2002 and June 2018. Our
database included patients enrolled in the GOLFIG-1 phase
II trial (49 cases), GOLFIG-2 phase III trial (EUDRACT:
2005-003458-81) (62 cases enrolled in the experimental arm
and 62 who received standard FOLFOX chemotherapy in the
control arm) (31, 34), and compassionate real-world therapy
(68 cases) after multiple treatment lines with FOLFOX/FOLFIRI
chemotherapy +/– cetuximab or bevacizumab (Table 1). All the
patients received the treatment atMOU-RC,MOU-SI,MOU-CZ,
ROU-SI, TOU-FI, and ICT-FL.
Posology Schedule
Gemcitabine (1,000 mg/m2) and oxaliplatin (85 mg/m2) were
administered to all patients twice a week, on days 1–5 and 2–
6, respectively, together with 5-FU as a bolus (400 mg/m2) and
TABLE 1 | Clinical features of 179 mCRC patients who received GOLFIG chemo-immunotherapy between June 2002 and June 2018.
Sex n. Treatment line n. Primary sidedness n. K/N-ras n. irAEs n.
Male 106 First line 62 Left 112 WT 41 No 136
Female 73 > 2 lines 117 Right 67 Mut 33 Yes 43
Sixty two of them had been enrolled in the GOLFIG-2 phase III trial and received frontline treatment. One hundred seventeen patients received salvage treatment after two/three treatment
lines. Forty-nine of them had been enrolled in the GOLFIG-1 phase II trial, and 68 received the GOLFIG chemo-immunotherapy as real-world treatment. mCRC, metastatic colorectal
cancer; GOLFIG, gemcitabine, oxaliplatin, LF, and fluorouracil poly-chemotherapy with granulocyte-macrophage colony stimulating factor and interleukin-2); irAEs, immune-related
adverse events.
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as a 24 h infusion (800 mg/m2) on days 1, 2, 15, and 16 and
levofolinate acid (100 mg/m2) on days 1, 2, 15, and 16. Moreover,
on days 3 and 7, 100 ug of s.c. GM-CSF was administered, and
on days 8–14 and 17–19, twice a day, an ultra-low-dose s.c.
recombinant interleukin-2 (rIL-2) (0.5× 106 IU) (34).
Evaluation
The standard assessment was performed at baseline and
every 4–6 weeks (clinical history, hemato-chemical analysis,
physical examination, CA19.9 and CEA assays, ultrasound scans,
and chest X-ray). Moreover, every 3 months, recorded high-
definition, multi-slice computed tomography scans with contrast
mediumwere recorded. According to the standardWHO criteria,
OS, PFS, overall response, and adverse events assessed were
evaluated. irAEs were also evaluated by an expert rheumatologist
and mainly consisted of a cutaneous rash, polyarthralgia, and
thyroiditis. There was one case of lupus discoides and one case of
Sjogren’s syndrome, both reported as case reports as long-lasting
patients (32, 33).
Patients enrolled in the GOLFIG-1 phase II trial and real-
word treatment received the treatment after one/two treatment
lines. Conversely, those enrolled in the GOLFIG-2 phase III
trial received the treatment as frontline upon randomization
in two different arms. Patients in the control arm received
standard treatment (according to guidelines defined in 2005)
with the FOLFOX-4 regimen, while those in the experimental
arm received the GOLFIG chemo-immunotherapy.
Criteria of inclusion were the mCRC confirmed diagnosis
(histology) and signed informed consent. Moreover, patients
had to show a normal renal, hepatic, and cardiac function;
an ECOG performance status ≤ 2; and a blood composition
not critically compromised (with more than 2,500 white
blood cells per mm3, more than 96 g of hemoglobin per
dL, and more than 100,000 platelets per mm3). Criteria of
exclusion were: the presence of other malignancies, active
infections, immunosuppression, and autoimmune major
diseases. Moreover, central nervous system involvement
and major organ failure were criteria for exclusion. The
study was approved by bioethical committees of the
different institutions and designed according to good clinical
practice recommendations.
During the GOLFIG-2 trial randomization and masking,
computer-generated patients’ randomization was carried out at
MOU-SI, and each recruiting center communicated with patients
by telephone/fax. An equal number of patients were randomly
assigned to the control arm (FOLFOX-4) or to the experimental
arm (GOLFIG). The allocation of the treatment was unmasked
(34). We have programmed to continue to enroll patients in
the future, administering the regimen in compassionate use
according to the availability of both GM-CSF and r-IL2.
Statistical Analysis
Our database, including these data, was used for our real-
world statistical analysis with a median follow-up of 15 years.
We used the Kaplan–Meier method to carry out descriptive
analyses. We estimated HR with Cox regression analysis and
compared OS and PFS between treatment groups with the
log-rank test. Using the median values as a cutoff, we then
transformed continuous variables into categorical variables and
performed a post-hoc subgroup analysis of OS and PFS for the
evaluation of characteristics of the different baselines of patients.
We constructed a forest plot to report the significance level of
single interactions, HR, and 95% CI.We used the w2 and Student
T-tests according to the continuous or dichotomic nature of the
variables to investigate their association. Moreover, to confirm
the role of significant variables in patients’ outcome, we used the
Cox proportional hazardmodel.We analyzed the data using SPSS
and GraphPad Prism 3.2 software.
RESULTS
Patient Population and Stratification
Our analysis included 179 mCRC patients. Sixty-two patients
who received the GOLFIG regimen as frontline treatment
had been enrolled in the GOLFIG-2 phase III trial. In that
study, an equivalent control cohort of 62 patients randomized
to receive the FOLFOX-4 regimen was also enrolled (34).
Further, 117 cases evaluated in the current study received the
GOLFIG regimen upon progression overmultiple treatment lines
(Table 1). Concerning the last group of patients, 49 cases had
been enrolled in the GOLFIG-1 phase II trial (30, 31), while
a further 68 received the treatment as compassionate use after
they had received FOLFOX and FOLFIRI+/– mAbs to VEGF or
EGFR as reported in Table 2.
Overall, were included 106 males and 73 females, with a
median age of 64 years and a median follow-up of 120 months,
with PS ECOG 0–2. The tumor was derived from the left colon
side in 112 patients and from the right side in the remaining 67
cases. K/N-ras mutational status was available for 74 pts, with 33
of them showing an activating K/N-ras mutation (Tables 1, 2).
Toxicity
The regimen proved to be quite safe in both chemo-
naïve and pre-treated patients. Grade 1–2 fever during sc.
aldesleukin administration was the most frequent adverse event
(39 patients; 19.5%). Low-grade (grade 1–2) asthenia/fatigue,
anemia, neutropenia, thrombocytopenia, and gastro-enteric
TABLE 2 | Clinical features of 68 mCRC patients who received the GOLFIG regimen on compassionate use between August 2008 and June 2018.
Sex ECOG Prev. Cht. lines Prev. mAbs to Radiotherapy Sidedness k/n-ras
Male Female ≤1 >1 1 ≥2 None EGFR VEGF Both Yes Not Left Right WT M“t ND
N 40 28 52 16 8 60 11 24 14 19 14 54 46 22 46 18 4
% 58.8 41.2 76.5 23.5 11.8 88.2 16.2 35.3 20.6 27.9 20.6 79.4 67.7 32.3 67.6 26.5 5.9
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toxicity were also recorded in 10–15% of the cases. In 6,
7, and 10 cases of pre-treated patients group, gastro-enteric
toxicity, thrombocytopenia, and grade 3–4 anemia episodes
(reversible) were reported, respectively. Twelve patients showed
hypersensitivity to oxaliplatin with hypotension, erythema,
dyspnea, and fever, while GM-CSF–related bone pain and
oxaliplatin-related neurologic toxicity were also recorded to
lesser extents (2–5%). After 4–9 months from the beginning of
the treatment, self-limiting irAEs were recorded in 49 patients
(24%), mainly consisting of mono/oligo-articular arthritis.
Discoid lupus erythematosus and Sjogren’s syndrome were
also described in two patients (32, 33). These events were
all self-limiting and/or controlled with non-steroidal anti-
inflammatory drugs (31, 34). There was no statistical difference
in irAE frequency comparing chemo-naïve with pre-treated
patients (P = 0.49).
Antitumor Activity
Overall, we found a mean PFS and OS of 15.28 [95% CI: 10.36–
20.20] and 24.61 [95% CI: 19.07–30.14] months, respectively,
with 14 patients who survived more than 10 years free of
progression (Figures 1A,B). In the present study, we performed
an updated analysis of the GOLFIG-2 trial in chemo-naïve
mCRC including 62 censored patients with a 10-year follow-up,
confirming that the GOLFIG regimen is superior to FOLFOX
alone in terms of PFS [9.4 vs. 5.8 months; HR = 0.58 (CI 0.39–
0.86), P = 0.006] and OS [17.3 vs. 12.9 months; HR = 0.69 (CI
0.47–1.03), P = 0.068] (Figures 1C,D).
These data confirmed the results of the previous analysis
performed on 84 censored patients (42 patients per arm) with a
much shorter follow-up (34).
The present study also demonstrated significant antitumor
activity in largely pre-treated patients, reporting a mean
PFS and OS of 12.55 [95% CI: 7.19–17.9] and 20.28 [95%
CI: 14.4–26.13] months, respectively (Figures 1E,F). These
results were of particular interest considering that 34 out
46 patients in the GOLFIG I trial had already received at
least a previous chemotherapy line according to the FOLFOX
regimen. Additionally, the majority of the 68 patients who
received the GOLFIG treatment in the compassionate setting
had already received multiple chemotherapy lines with FOLFOX
and FOLFIRI regimens +/– mAbs to EGFR or VEGF (Table 2)
according to the current guidelines. This real-life subset of
patients showed a mean PFS and OS of 8.19 (4.8–11.5) and 19.19
(12.98–25.29) months, respectively (Figures 1G,H), which was
perfectly in line with what was recorded in the original study.
Further analyses were also carried out to investigate patients’
outcome correlation with baseline neutrophil counts, irAEs,
sidedness, mutational K/N-ras status, age, sex, performance
status (ECOG ≤1), and multiple chemotherapy lines, finding
that both PFS and OS were positively correlated with baseline
neutrophil counts ≤ 4.500 cells/µl [HR: 0.32 (CI 0.21–0.45), P
= 0.003] and occurrence of irAEs [HR = 0.36 (CI 0.25–0.53),
P = 0.0001] only [Figures 2A–D and data not shown]. In fact,
sidedness, mutational K/N-ras status, age, sex, and performance
status (ECOG ≤1) did not correlate with both PFS and OS.
DISCUSSION
This study was performed to define the safety and antitumor
activity of GOLFIG chemo-immunotherapy in mCRC patients
on a long-lasting follow-up and also carried out an updated
analysis on the GOLFIG-2 trial as frontline treatment of these
patients (35). The present analysis of the GOLFIG-2 trial
performed on a larger series of patients (124 vs. 98 cases evaluated
in the last analysis in 2013) confirmed the superiority of GOLFIG
chemo-immunotherapy over a FOLFOX-4 regimen as frontline
treatment in terms of PFS, also reporting a trend to a prolonged
survival in the GOLFIG arm (HR = 0.69; P = 0.06), with 7.8%
of these patients and none in the FOLFOX arm alive and free
of progression after 10 years, fulfilling the primary objective of
the original study (34). These results are of interest considering
that the study could also include symptomatic patients with a
low performance status (ECOG≤2) who usually are excluded by
the combined use of mAbs due to the high risk of toxicity (34),
and that the trial allowed the possibility to use free second-line
poly-chemotherapy in combination with anti-VEGF and anti-
EGFR mAbs. Additionally, we should take into consideration
that the most reliable frontline treatments at the present achieve
an average RR of 34–55% and a PFS of 7–9 months, similar
to what was reported in the GOLFIG arm but associated with
more frequent adverse events and 10-times-higher costs. This
evidence, although obtained on a small sample of patients,
provides a strong rationale to continue the investigation on the
GOLFIG regimen alone and in combination with anti-EGFR and
VEGF mAbs.
Our current analysis was also performed on largely treated
mCRC patients, including 49 patients enrolled in the GOLFIG-
1 phase II trial (30, 31) and 68 treated on compassionate use after
the progressed multiple treatment polylines alone or associated
with anti-EGFR and VEGF mABs.
The GOLFIG-1 was a phase II trial designed on the clinical
translation of preclinical immuno-oncological results (28–31)
and started in 2002, long before either bevacizumab or cetuximab
was available for the standard treatment of mCRC patients. The
schedule was designed on the basis of the strong preclinical and
clinical evidence that the addition of gemcitabine to oxaliplatin,
5-FU, and LF strongly potentiated both the direct anti-cancer
effects and the immunological properties of the tumor. The
results of that trial, including a small sample of patients, were
encouraging in terms of safety, RR [56.5% (95% CI: 42.1–
69.8)] and average time to progression (12.26, 95% CI: 9.2–
15.2 months) (31). In the present analysis, we included an
additional real-life sample of 68 mCRC patients who received
the GOLFIG regimen on compassionate use starting in 2009
when the current guidelines for mCRC treatment had already
been defined. This patient cohort, therefore, had been screened
for K/N-ras mutational status and received accordingly at
least two poly-chemotherapy lines +/– mAbs to VEGF and/or
EGFR prior to receiving the GOLFIG chemo-immunological
treatment. Our analysis confirmed the promising antitumor
activity of the GOLFIG in mCRC patients, where we recorded
a PFS and an OS of 12.55 and 20.28 months, respectively,
which was not correlated to age, sex, sidedness, and K/N-ras
Frontiers in Oncology | www.frontiersin.org 5 November 2019 | Volume 9 | Article 1102
Caraglia et al. GOLFIG: 15 Years’ Real-World Evidence
FIGURE 1 | (A–H) Panels A and B represent PFS (A) and OS (B) of metastatic colorectal cancer (mCRC) patients who received the GOLFIG (gemcitabine, oxaliplatin,
LF, and fluorouracil poly-chemotherapy with granulocyte-macrophage colony stimulating factor and interleukin-2) regimen and enrolled in the GOLFIG-1 trial,
GOLFIG-2 trial, and real-world treatment. (C,D) represent the updated results of the GOLFIG-2 trial including 124 mCRC patients randomized to receive frontline
treatment with GOLFIG regimen (62 pts) or FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) chemotherapy (62 pts). GOLFIG showed superiority over
FOLFOX in terms of PFS (C) and a trend to superiority in terms of OS (D). All of the patients were allowed a free second line with or without anti–epidermal growth
factor receptor (EGFR) or vascular-endothelial growth factor (VEGF) monoclonal antibodies (mABs). (E,F) represents the PFS (E) and OS (F) of mCRC patients who
received GOLFIG chemo-immunotherapy as frontline (62 pts enrolled in the GOLFIG-2 trial) or second/third line (117 patients, of whom 49 enrolled in the GOLFIG-1
trial and the remaining as real-world treatment). (G,H) represent PFS (G) and OS (H) of the real-life subset of patients.
mutational status in previous treatment lines. The present study
confirmed the occurrence of irAEs in 24% of the patients
who received the chemo-immunological treatment that was
correlated to a longer OS. This finding, together with the previous
immunological results reported in the previous study (35–37),
strongly supports the hypothesis of an effective immune-
response involvement triggered by this chemo-immunotherapy
regimen. In line with the literature, the activity of GOLFIG
chemo-immunotherapy was explained on the hypothesis that a
longer survival mainly depends on the presence of an efficient
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FIGURE 2 | (A–D) Panels A and B represent PSF (A) and OS (B) of 179 mCRC patients who received GOLFIG chemo-immunotherapy with left (112 pts) and right
primary sidedness (67 pts). (C,D) represent PFS (C) and OS (D) of 74 mCRC patients who received GOLFIG chemo-immunotherapy with wt (41 pts) and mutated
K/N-ras (33 pts). Both primary tumor sidedness and K/N-ras mutational status did not influence the outcome of these patients.
host’s immune response (38) consequent to cytotoxic drugs
able to induce immunogenic cell death and autophagy (39)
and antigen remodeling and promote immunological danger
signals that, in turn, may empower an efficient tumor-specific
immune response (40–43). There is additional evidence that
cytotoxic drugs such as 5-FU, gemcitabine, or oxaliplatin may
selectively kill PDL-1/-2+ immunosuppressive inflammatory
cells or Treg cells (26, 31, 34, 38, 40). In line with this
evidence, the results of our previous studies showed in
these patients GOLFIG treatment-related empowerment of
innate immunity, DC-mediated immune-priming, cytotoxic
Th1 immune-phenotype, and Tcm cell response paralleled by
a progressive decline in immunosuppressive Tregs (31, 34).
Altogether, these results were also in line with the occurrence of
irAEs and its correlation with a good outcome in these patients.
Additionally, this is the only immune-oncological treatment
that has shown effective antitumor activity in mCRC; the use
of PD-1/PDL-1 blockade mAbs, which have been so successful
in other common malignancies, has failed in these patients,
excluding those bearing a mismatch repair deficiency (14, 15),
even in the presence of tumor-specific CTLs. The reasons for
this downfall are not completely known, even though it seems
to be correlated with a very immunosuppressive colon cancer
micro-environment (14), the same micro-environment that may
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be significantly modified by the use of the GOLFIG regimen.
This hypothesis is supported by the promising results of a recent
phase Ib trial where the TSPP vaccine to the tumor-associated
thymidylate enzyme showed significant immune-biological and
antitumor activity in mCRC patients who received a prior
chemo-immunological treatment according to the GOLFIG
regimen (44, 45).
In conclusion, our clinical results confirm that the GOLFIG
regimen is a competitive regimen for fit mCRC patients who
had undergone standard frontline chemotherapy +/– mABs.
The new findings derived from the present manuscript are
the following: (i) the updated analysis of the GOLFIG-2 trial
in chemo-naïve mCRC including 62 censored patients with
a 15-year follow-up confirmed that the GOLFIG regimen is
superior to FOLFOX alone in terms of PFS with a trend of
a prolonged OS; (ii) the present study also demonstrated a
significant antitumor activity in largely pre-treated patients, and
7.8% of these patients and none in the FOLFOX arm were
alive and free of progression after 10 years; and (iii) both PFS
and OS were positively correlated to baseline neutrophil counts
and occurrence of irAEs, while sidedness, mutational K/N-ras
status, age, sex, and performance status did not correlate. The
results of this study maintain an open door on the use of
GOLFIG in mCRC patients, which deserves further prospective
studies. Additionally, these results warrant the idea of testing
a combinatory approach of cytotoxic chemotherapy, immune-
stimulating cytokines, and immune-checkpoint blockade.
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